Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Lightspeed Venture Partners","pharmaFlowCategory":"D","amount":"$101.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Development Integrating Machine Learning","therapeuticArea":"Immunology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Seismic Therapeutic","sponsor":"Bessemer Venture Partners","pharmaFlowCategory":"D","amount":"$21.0 million","upfrontCash":"Undisclosed","newsHeadline":"Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"}]

    Find Clinical Drug Pipeline Developments & Deals by Seismic Therapeutic

    Menu

    Seismic Therapeutic

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Seismic Therapeutic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Seismic Therapeutic Closes $121 Million Series B Financing to Advance Immunology Pipeline Optimized by its Machine Learning Platform

              Details:

              The net proceeds will be used to advance through Phase 1 proof-of-mechanism trials with Seismic’s two lead programs, a pan‑immunoglobulin G protease sculpting enzyme candidate, S-1117 and a PD-1 agonist:Fc gamma receptor IIb selective DcB antibody candidate, S-4321.

              Lead Product(s): S-1117

              Therapeutic Area: Immunology Product Name: S-1117

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: Bessemer Venture Partners

              Deal Size: $21.0 million Upfront Cash: Undisclosed

              Deal Type: Series B Financing December 04, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Seismic Therapeutic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Seismic Therapeutic Launches with $101 Million Series A Financing to Usher in a New Era of Immunology Drug Development Integrating Machine Learning

              Details:

              The Series A financing will support Seismic Therapeutic’s further advancement toward the clinic of its first two lead drug programs, one targeting Ig (immunoglobulin)-mediated autoimmunity and the other targeting cell-mediated autoimmunity.

              Lead Product(s): Undisclosed

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Lightspeed Venture Partners

              Deal Size: $101.0 million Upfront Cash: Undisclosed

              Deal Type: Series A Financing February 09, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY